Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $17.30 USD
Change Today -0.29 / -1.65%
Volume 185.0K
PETX On Other Exchanges
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

aratana therapeutics inc (PETX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/15 - $20.63
52 Week Low
10/2/14 - $9.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

aratana therapeutics inc (PETX) Related Businessweek News

View More BusinessWeek News

aratana therapeutics inc (PETX) Details

Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of biopharmaceutical products for the companion animals worldwide. Its product portfolio includes approximately 18 therapeutic candidates consisting of small molecule pharmaceuticals and large molecule biologics that target various opportunities in serious medical conditions in pets. The company develops AT-001, a prostaglandin E receptor 4 antagonist to treat the osteoarthritis pain in dogs, and degenerative joint disease in cats; AT-002, a ghrelin agonist for stimulation of appetite in dogs, as well as for weight gain in cats and dogs; AT-003, a bupivacaine liposome injectable suspension for the treatment of post-operative pain in cats and dogs; AT-004, a monoclonal antibody (MAB) used in the treatment of B-cell lymphoma in dogs; and AT-005, a caninized MAB for the treatment of T-cell lymphoma in dogs. It also develops other products, such as AT-006 for treatment of ocular lesions caused by feline herpes virus; AT-007 for the treatment of cats infected with feline immunodeficiency virus; AT-008, a small molecule for the treatment of canine lymphoma; AT-009, a caninized MAB used as an aid in the treatment of canine mast cell tumors; AT-010, a caninized MAB used as an aid for the treatment of atopic dermatitis in dogs; AT-011 to treat parvovirus in dogs; and AT-012 for treatment of feline calicivirus in cats. In addition, the company develops AT-015, a felinized MAB intended as an aid in the treatment of cat lymphoma; AT-016 that provides long-term relief of pain and disability caused by osteoarthritis through regeneration of joint damage; AT-017, a lymphoma immunotherapy for dog lymphoma; and AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Kansas City, Kansas.

49 Employees
Last Reported Date: 03/16/15
Founded in 2010

aratana therapeutics inc (PETX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $467.5K
Chief Financial Officer and Treasurer
Total Annual Compensation: $350.0K
Chief Development Officer
Total Annual Compensation: $302.5K
Chief Commercial Officer
Total Annual Compensation: $302.5K
Chief Scientific Officer
Total Annual Compensation: $321.9K
Compensation as of Fiscal Year 2014.

aratana therapeutics inc (PETX) Key Developments

Aratana Therapeutics Elects Wendy Yarno as Chairman of the Board of Directors

Aratana Therapeutics, Inc. announced that the Board of Directors has elected Wendy Yarno as Chairman of Aratana's Board of Directors. She will replace Jay Lichter, Ph.D., who has resigned from the Board. Ms. Yarno has been a member of Aratana's Board since 2013. In addition to her board position with Aratana, Ms. Yarno currently holds public company board positions with St. Jude Medical, Inc. and Medivation, Inc.

Aratana Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Financial Guidance for the Full Year of 2015

Aratana Therapeutics, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $230,000 compared to $300,000 a year ago. Loss from operations was $11,345,000 compared to $9,503,000 a year ago. Loss before income taxes was $8,343,000 compared to $9,613,000 a year ago. Net loss was $7,983,000 or $0.23 per basic and diluted share compared to $9,278,000 or $0.32 per basic and diluted share a year ago. For the six months, the company reported total revenues of $386,000 compared to $476,000 a year ago. Loss from operations was $22,208,000 compared to $18,725,000 a year ago. Loss before income taxes was $17,388,000 compared to $19,392,000 a year ago. Net loss was $16,757,000 or $0.49 per basic and diluted share compared to $18,430,000 or $0.66 per basic and diluted share a year ago. The Company has used $17.8 million in cash from operations during the first six months of 2015. The company purchased $1.1 million of capital assets in the first 6 months for improvements in its operating infrastructure and manufacturing operations. The company believes it continues to make fiscally responsible investments in its business and currently anticipates completing the year on the lower end of the operating cash use guidance provided of $45 million to $55 million. The company continues to expect that its cash, cash equivalents, and short-term investments will fund operations through December 31, 2016.

Aratana Therapeutics, Inc. Announces Positive Pilot Field Study of AT-002 in Cats

Aratana Therapeutics, Inc. announced the positive results of a pilot field study of AT-002 (capromorelin) in cats. Capromorelin is a small molecule that mimics ghrelin, the naturally occurring hormone that stimulates appetite, increases body weight and increases serum growth hormone levels. The multi-site, placebo-controlled, pilot field study of approximately 40 cats measured weight gain/loss in cats with chronic kidney disease and documented weight loss who received AT-002 at a dose of 2 mg/kg compared to cats that received placebo treatment. Both groups were treated orally once daily for 90±3 days. Aratana also reported the results of a separate placebo-controlled laboratory study in 24 beagle dogs who received AT-002 once daily at 3 mg/kg or placebo once daily for 4 days.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PETX:US $17.30 USD -0.29

PETX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Kindred Biosciences Inc $6.05 USD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation PETX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 938.2x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 811.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARATANA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at